Cargando…
Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group
BACKGROUND: We studied the maximum tolerated dose (MTD) and efficacy of oxaliplatin added to capecitabine and radiotherapy (Capox-RT) as neoadjuvant therapy for rectal cancer. METHODS: T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2039827/ https://www.ncbi.nlm.nih.gov/pubmed/17653805 http://dx.doi.org/10.1245/s10434-007-9396-6 |
_version_ | 1782137057337933824 |
---|---|
author | Hospers, Geke A. Punt, Cornelis J. A. Tesselaar, Margot E. Cats, Annemieke Havenga, Klaas Leer, Jan W. H. Marijnen, Corrie A. Jansen, Edwin P. Van Krieken, Han H. J. M. Wiggers, Theo Van de Velde, Cornelis J. H. Mulder, Nanno H. |
author_facet | Hospers, Geke A. Punt, Cornelis J. A. Tesselaar, Margot E. Cats, Annemieke Havenga, Klaas Leer, Jan W. H. Marijnen, Corrie A. Jansen, Edwin P. Van Krieken, Han H. J. M. Wiggers, Theo Van de Velde, Cornelis J. H. Mulder, Nanno H. |
author_sort | Hospers, Geke A. |
collection | PubMed |
description | BACKGROUND: We studied the maximum tolerated dose (MTD) and efficacy of oxaliplatin added to capecitabine and radiotherapy (Capox-RT) as neoadjuvant therapy for rectal cancer. METHODS: T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabine of 1000 mg/m(2) twice daily (days 1–14, 25–38) added to RT with 50.4 Gy and surgery after 6–8 weeks. The MTD, determined during phase I, was used in the subsequent phase II, in which R0 resection rate (a negative circumferential resection margin) was the primary end point. RESULTS: Twenty-one patients were evaluable. In the phase I part, oxaliplatin at 85 mg/m(2) was established as MTD. In phase II, the main toxicity was grade III diarrhea (18%). All patients underwent surgery, and 20 patients had a resectable tumor. An R0 was achieved in 17/21 patients, downstaging to T0-2 in 7/21 and a pCR in 2/21. CONCLUSION: Combination of Capox-RT has an acceptable acute toxicity profile and a high R0 resection rate of 81% in locally advanced rectal cancer. However the pCR rate was low. |
format | Text |
id | pubmed-2039827 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-20398272007-10-29 Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group Hospers, Geke A. Punt, Cornelis J. A. Tesselaar, Margot E. Cats, Annemieke Havenga, Klaas Leer, Jan W. H. Marijnen, Corrie A. Jansen, Edwin P. Van Krieken, Han H. J. M. Wiggers, Theo Van de Velde, Cornelis J. H. Mulder, Nanno H. Ann Surg Oncol Gastrointestinal Oncology BACKGROUND: We studied the maximum tolerated dose (MTD) and efficacy of oxaliplatin added to capecitabine and radiotherapy (Capox-RT) as neoadjuvant therapy for rectal cancer. METHODS: T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabine of 1000 mg/m(2) twice daily (days 1–14, 25–38) added to RT with 50.4 Gy and surgery after 6–8 weeks. The MTD, determined during phase I, was used in the subsequent phase II, in which R0 resection rate (a negative circumferential resection margin) was the primary end point. RESULTS: Twenty-one patients were evaluable. In the phase I part, oxaliplatin at 85 mg/m(2) was established as MTD. In phase II, the main toxicity was grade III diarrhea (18%). All patients underwent surgery, and 20 patients had a resectable tumor. An R0 was achieved in 17/21 patients, downstaging to T0-2 in 7/21 and a pCR in 2/21. CONCLUSION: Combination of Capox-RT has an acceptable acute toxicity profile and a high R0 resection rate of 81% in locally advanced rectal cancer. However the pCR rate was low. Springer-Verlag 2007-07-26 2007-10 /pmc/articles/PMC2039827/ /pubmed/17653805 http://dx.doi.org/10.1245/s10434-007-9396-6 Text en © Society of Surgical Oncology 2007 |
spellingShingle | Gastrointestinal Oncology Hospers, Geke A. Punt, Cornelis J. A. Tesselaar, Margot E. Cats, Annemieke Havenga, Klaas Leer, Jan W. H. Marijnen, Corrie A. Jansen, Edwin P. Van Krieken, Han H. J. M. Wiggers, Theo Van de Velde, Cornelis J. H. Mulder, Nanno H. Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group |
title | Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group |
title_full | Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group |
title_fullStr | Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group |
title_full_unstemmed | Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group |
title_short | Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group |
title_sort | preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. a phase i–ii multicenter study of the dutch colorectal cancer group |
topic | Gastrointestinal Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2039827/ https://www.ncbi.nlm.nih.gov/pubmed/17653805 http://dx.doi.org/10.1245/s10434-007-9396-6 |
work_keys_str_mv | AT hospersgekea preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT puntcornelisja preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT tesselaarmargote preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT catsannemieke preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT havengaklaas preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT leerjanwh preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT marijnencorriea preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT jansenedwinp preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT vankriekenhanhjm preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT wiggerstheo preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT vandeveldecornelisjh preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup AT muldernannoh preoperativechemoradiotherapywithcapecitabineandoxaliplatininlocallyadvancedrectalcanceraphaseiiimulticenterstudyofthedutchcolorectalcancergroup |